SCYNEXIS, Inc. completa US$13,5 millones en financiación
March 27, 2008 17:12 ET
|
SCYNEXIS, INC.
RESEARCH TRIANGLE PARK, NC--(Marketwire - March 27, 2008) -
SCYNEXIS, Inc., una compañía líder en descubrimiento y desarrollo de medicamentos, anunció hoy que ha terminado...
SCYNEXIS, Inc. schließt Finanzierung mit 13,5 Mio. USD ab
March 27, 2008 14:55 ET
|
SCYNEXIS, INC.
RESEARCH TRIANGLE PARK, NC--(Marketwire - March 27, 2008) -
SCYNEXIS, Inc., ein führendes, in der Wirkstoffentdeckung und -entwicklung tätiges Unternehmen, gab heute den mit 13,5 Mio. USD...
SCYNEXIS, Inc. Completes $13.5 Million Financing
March 27, 2008 08:45 ET
|
SCYNEXIS, INC.
RESEARCH TRIANGLE PARK, NC--(Marketwire - March 27, 2008) - SCYNEXIS, Inc., a premier drug
discovery and development company, today announced the successful
completion of a $13.5 million Series C-2...
SCYNEXIS to Present at the JPMorgan Healthcare Conference on January 8, 2008
January 07, 2008 10:00 ET
|
SCYNEXIS, INC.
RESEARCH TRIANGLE PARK, NC--(Marketwire - January 7, 2008) - SCYNEXIS, Inc. announced today
its participation in the 26th Annual JPMorgan Healthcare Conference,
January 7-10, 2008 at the Westin St....
SCYNEXIS erhält Zahlung von Merial für Erreichen gemeinschaftlicher Forschungsziele
December 13, 2007 08:00 ET
|
SCYNEXIS, INC.
RESEARCH TRIANGLE PARK, NC--(Marketwire - December 13, 2007) -
SCYNEXIS, Inc. gab heute bekannt, dass es für das Erreichen festgelegter Teilforschungsziele im Rahmen seiner mehrjährigen...
SCYNEXIS recibe pago como recompensa por la colaboración investigadora con Merial
December 13, 2007 08:00 ET
|
SCYNEXIS, INC.
RESEARCH TRIANGLE PARK, NC--(Marketwire - December 13, 2007) -
SCYNEXIS, Inc. anunció hoy que ha recibido un pago por cumplir con ciertos requisitos en su colaboración investigadora con...
SCYNEXIS Receives Merial Research Collaboration Milestone Payment
December 13, 2007 08:00 ET
|
SCYNEXIS, INC.
RESEARCH TRIANGLE PARK, NC--(Marketwire - December 13, 2007) - SCYNEXIS, Inc. announced today
that it has earned a payment for meeting certain milestones in its
multi-year research collaboration with...
SCYNEXIS et DNDi passent un accord pluriannuel historique pour identifier des candidats aux traitements destinés à soigner la maladie du sommeil
November 05, 2007 08:30 ET
|
SCYNEXIS, INC.
RESEARCH TRIANGLE PARK, NC et GENEVA, SWITZERLAND--(Marketwire - November 5, 2007) -
SCYNEXIS
et l'organisation "Médicaments pour les initiatives dédiées aux maladies...
SCYNEXIS and DNDi Enter Landmark Multi-Year Agreement to Identify Drug Candidates to Treat Sleeping Sickness
November 05, 2007 08:30 ET
|
SCYNEXIS, INC.
RESEARCH TRIANGLE PARK, NC and GENEVA, SWITZERLAND--(Marketwire - November 5, 2007) - SCYNEXIS
and Drugs for Neglected Diseases initiative (DNDi) have agreed to
collaborate on vital drug discovery...
Viniterra Development Experiences Successful Weekend Sales Launch
October 26, 2007 12:22 ET
|
Viniterra Residential Development
NEW KENT, VA--(Marketwire - October 26, 2007) - Viniterra, the new residential community with
unique luxury amenities that include a picturesque winery, world-class
designed championship golf course,...